Lung cancer and immunotherapy: a real-life experience from second line and beyond.
Aim: This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Materials & methods: Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. Results: One hundred and ten patients were included with PD-L1 expression above 50%, between 1-49 and <1% in 38.6, 27.3 and 34.1% of patients, respectively. Checkpoint inhibitors were used as second, third and fourth line in 74.7, 21.8 and 3.5%, respectively. Partial response was observed in 25.6% of patients. Median progression-free survival was 4 months and median overall survival was 8.1 months. Conclusion: Immunotherapies are emerging as important tools in the oncologic field with good responses in real-life practice.
['El Karak|Fady|F|', 'Gh Haddad|Fady|F|', 'Eid|Roland|R|', 'Al Ghor|Maya|M|', 'El Rassy|Elie|E|', 'Ahmadieh|Nizar|N|', 'Choullamy|Theresia|T|', 'Halim|Nour A|NA|', 'Tfayli|Arafat|A|', 'Farhat|Fadi|F|', 'Kattan|Joseph|J|', 'Nasr|Fady|F|', 'Ghosn|Marwan|M|', 'Assi|Hazem I|HI|']
D000368:Aged D000074322:Antineoplastic Agents, Immunological D060890:B7-H1 Antigen D014408:Biomarkers, Tumor D005260:Female D006801:Humans D007167:Immunotherapy D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D011379:Prognosis D019233:Retreatment D016176:T-Lymphocyte Subsets D016896:Treatment Outcome
lung cancer immunotherapy experience second line real life non-small-cell lung cancer checkpoint inhibitors real-world